Boston Scientific's PROMUS Element(TM) Platinum Chromium Stent System Demonstrates Comparable Safety and Effectiveness Outcomes Versus Leading Drug-eluting Stent in Platinum Workhorse Trial

Reduction of Geographic Miss and Bail-out Stenting Observed With Highly Visible PROMUS Element Stent

NATICK, Massachusetts and NEW ORLEANS, April 5, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced
12-month results from the pivotal PLATINUM Workhorse trial comparing the
safety and effectiveness of the PROMUS Element(TM) Everolimus-Eluting
Platinum Chromium (PtCr) Coronary Stent System to the PROMUS(R)
Everolimus-Eluting Coronary Stent System. The trial demonstrated the clinical
non-inferiority of the PROMUS Element Stent in comparison to the PROMUS Stent
in treating de novo coronary artery lesions while showing a procedural
benefit of reduced rates of unplanned (bail-out or emergency) stenting.

Results were presented during a late-breaking trial session at
the American College of Cardiology Annual Scientific Sessions by Gregg W.
Stone, M.D., Professor of Medicine and Director of Research and Education at
the Center for Interventional Vascular Therapy at Columbia University Medical
Center/New York-Presbyterian Hospital and Global Principal Investigator of
the trial. Results were also published concurrently in the online version of
the Journal of American College of Cardiology (JACC) and will be available in
the April 19 print edition.

"The PROMUS Element Platinum Chromium Stent met the primary
non-inferiority endpoint of target lesion failure at one year compared to the
PROMUS Stent while demonstrating excellent safety and effectiveness with low
rates of cardiac death, myocardial infarction, stent thrombosis and
revascularization," said Dr. Stone. "The remarkably low rates of stent
thrombosis and target lesion revascularization at one year confirm the
successful transfer of the favorable outcomes associated with everolimus to
the novel platinum chromium stent design."

The primary endpoint of non-inferiority for the PROMUS Element
Stent compared to the PROMUS Stent was met with a 12-month target lesion
failure (TLF) rate in the per protocol population of 3.4 percent versus 2.9
percent, respectively (pNI=0.001). No statistically significant differences
in TLF components were observed between the two stents. In the
intention-to-treat population, TLF (3.5 percent vs. 3.2 percent, p=0.72),
cardiac death related to the target vessel (0.8 percent vs. 0.4 percent,
p=0.51), myocardial infarction (MI) related to the target vessel (0.8 percent
vs. 1.6 percent, p=0.14) and ischemia-driven target lesion revascularization
(TLR, 1.9 percent vs. 1.9 percent, p=0.96) were all similar. Low rates of
target vessel revascularization (TVR, 2.7 percent vs. 2.9 percent, p=0.83)
and stent thrombosis (ARC definite/probable, 0.4 percent vs. 0.4 percent,
p=0.99) were also observed at 12 months for the PROMUS Element and PROMUS
Stents.

Both stents achieved high rates of technical success (99.4
percent for PROMUS Element vs. 98.8 percent for PROMUS, p=0.14) indicating
successful delivery and deployment of the stent to the target vessel. The
PROMUS Element Stent achieved a significant reduction in unplanned (bail-out
or emergency) stenting (5.9 percent vs. 9.8 percent, p=0.004), including a
significantly lower rate of inadequate lesion coverage (1.4 percent vs. 3.4
percent, p=0.01). These clinical observations are consistent with the results
of comparative bench and animal studies, which have demonstrated the enhanced
visibility of the PROMUS Element Stent relative to the PROMUS Stent.

"We are extremely pleased that the highly opaque platinum
chromium alloy PROMUS Element Stent significantly reduced both inadequate
lesion coverage ('geographic miss') and the need for unplanned (bail-out)
stenting," said Hank Kucheman, Executive Vice President and Group President,
Cardiology, Rhythm and Vascular for Boston Scientific. "The PROMUS Element
Stent offers interventional cardiologists a true next-generation stenting
option for patients with coronary artery disease."

The PROMUS Element Stent System received CE Mark approval and
was launched in Europe and other international markets in 2009. It features
an innovative PtCr alloy and new stent design to offer greater strength,
enhanced deliverability and exceptional visibility. The thin-strut stent is
designed for improved conformability, minimal recoil, and uniform lesion
coverage and drug distribution. The advanced low-profile delivery system
facilitates precise delivery of the stent across challenging lesions.

The PLATINUM clinical program is evaluating the safety and
effectiveness of the PROMUS Element Stent in five multi-center studies
totaling more than 1,800 patients, including single-arm studies evaluating
small vessels, long lesions, pharmacokinetics, and quantitative coronary
angiography and intravascular ultrasound data. PLATINUM Workhorse is a
global, randomized, pivotal controlled trial designed to support U.S. Food
and Drug Administration (FDA) approval of the PROMUS Element Stent System.
The trial enrolled 1,530 patients with up to two de novo lesions at 132 sites
worldwide, and completed enrollment in September 2009.

The PERSEUS clinical program compared the ION (TAXUS Element)
Stent to prior-generation Boston Scientific stents in more than 1,600
patients in two parallel trials at 90 centers worldwide. The PERSEUS
Workhorse trial reported 12-month results in March 2010, demonstrating
positive safety and efficacy outcomes in workhorse lesions for the ION Stent
System compared to the TAXUS(R) Express(2)(R) Stent System.

The Company anticipates FDA approval for the PROMUS Element
Stent in mid 2012. In the U.S., the PROMUS Element Stent is an
investigational device, limited by applicable law to investigational use only
and not available for sale.

In the U.S., the TAXUS Element Stent System will be
commercialized as the ION(TM) Paclitaxel-Eluting Platinum Chromium Coronary
Stent System. In the U.S., the ION Stent System is an investigational device,
limited by applicable law to investigational use only and not available for
sale. The Company expects to launch the ION Stent System in the United States
by mid-2011. The TAXUS Element Stent System received CE Mark approval in May
2010.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Forward-looking statements may be
identified by words like "anticipate," "expect," "project," "believe,"
"plan," "estimate," "intend" and similar words. These forward-looking
statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements include,
among other things, statements regarding new product launches and launch
cadence, regulatory approvals, clinical trials, product performance, and
impact on the coronary stent market and competitive offerings. If our
underlying assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially from the
expectations and projections expressed or implied by our forward-looking
statements. These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press release. As a
result, readers are cautioned not to place undue reliance on any of our
forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A -
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

    CONTACT: Erik Kopp
    +1-508-650-8660 (office)
    Media Relations
    Boston Scientific Corporation
    erik.kopp@bsci.com

    Sean Wirtjes
    +1-508-652-5305 (office)
    Investor Relations
    Boston Scientific Corporation
    investor_relations@bsci.com

CONTACT: Erik Kopp, +1-508-650-8660 (office), Media Relations, Boston Scientific Corporation,
erik.kopp at bsci.com; Sean Wirtjes, +1-508-652-5305 (office), Investor Relations,
Boston Scientific Corporation, investor_relations at bsci.com